ALL WALES PRESCRIBING ADVISORY GROUP

Similar documents
National Prescribing Indicators Annual Primary Care Prescribing Report

NHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014

National Prescribing Indicators Analysis of Prescribing Data to September 2015

NHS WALES PRIMARY CARE PRESCRIBING ANALYSIS: TRAMADOL. April 2013

NATIONAL PRESCRIBING INDICATORS ANALYSIS OF PRESCRIBING DATA TO DECEMBER 2014

DRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.

In this edition: Newsletter Summer How Primary Care can help earlier diagnosis. Improving communication between Primary & Secondary Care

8 Public Health Wales CDSC Weekly Influenza Surveillance Report Wednesday 21 August 2013 (covering week )

Wales Primary Care COPD Audit

Tramadol Educational Resource Materials. Educational Slide Set

National COPD Audit Programme

Persistent Pain Resources. Educational Slide Set

All Wales Lymphoedema Service and Community Pharmacy Wales Collaborative Project Terms of Reference (ToR)

Community Pharmacy Influenza Vaccination A summary of the results of the national Community Pharmacy Seasonal Influenza Vaccination Service

FORMULARY UPDATES ABUHB s Drug Formulary is at:

HIGH BLOOD PRESSURE. How can we do better?

Annual statement of progress Liver Disease Delivery Plan May 2017

Public Health Wales CDSC Weekly Influenza Surveillance Report Wednesday 21 st January 2015 (covering week )

National Standards for Acute Oncology Services

The All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.

Clostridium difficile (C. difficile) and Staphylococcus aureus bacteraemia (MRSA and MSSA) Bi-annual Report. Surveillance: Report:

Respiratory Prescribing Analysis with Cluster Level Comparators

Storyboard submission

Lower your risk of stroke. Community pharmacy public health campaign report

WELSH HEALTH CIRCULAR

The RPS is the professional body for pharmacists in Wales and across Great Britain. We are the only body that represents all sectors of pharmacy.

KC53/61/65 Statistical Report Adroddiad Ystadegol 2012/13 Prepared by Cervical Screening Wales

Stop Smoking Wales Annual Report

National Lymphoedema Strategy Programme. End of Year Report 2012/13 and Work Programme for 2013/14. Fiona Jenkins /Jane Fitzpatrick / Melanie Thomas

National Prescribing Indicators Supporting Information for Prescribers

PICTURE OF ORAL HEALTH 2012 DENTAL EPIDEMIOLOGICAL SURVEY OF 5 YEAR OLDS

NATIONAL PRESCRIBING INDICATORS ANALYSIS OF PRESCRIBING DATA: DECEMBER April 2013

Aneurin Bevan Health Board. Measles Emergency Response

Prescribing of Denosumab (Prolia ) in Wales: Review. Full document

In your area: BMA Cymru Wales

Haematology Advisory Group Meeting

Polypharmacy: Guidance for Prescribing Figure 2: A Practical Guide to Stopping Medication in the Elderly

Powys teaching Health Board. Local Healthcare Professionals Forum. Terms of Reference - DRAFT

Yellow Card Centre Scotland Centre for Adverse Reactions to Drugs (Scotland)

Freedom of Information Act Request Rookwood Hospital

Seasonal influenza in Wales 2016/17

Process for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases Effective from September 2015

Forecasting and Monitoring Budgetary impact and medicines uptake

Aneurin Bevan Health Board. Screening Programmes

MONITORING OF MEDICINES APPRAISED BY NICE AND AWMSG SUMMARY

Newborn Bloodspot Screening (NBS) Training for Health Visitors. December 2017

Evaluation of the computer-based CBT programme pilot at rural community pharmacies in Gwynedd

Use of anti-psychotic medication in care homes Response from the Royal Pharmaceutical Society in Wales

2014/15 ANNUAL REPORT OF THE POWYS HEART DISEASE DELIVERY PLAN. Director of Public Health. Director of Public Health

Quality & Safety Committee

Minutes of the meeting of the NHS Nottingham City CCG People s Council

Lung Cancer 2013 Peer Review All Wales Report

pat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16

Tuberculosis in Wales Annual Report 2013

Welsh Cancer Intelligence and Surveillance Unit Uned Gwybodaeth a Gwyliadwriaeth Canser Cymru

The Single Cancer Pathway

Uptake of pertussis and influenza vaccination in pregnant women in Wales

Polypharmacy and Deprescribing. A special report on views from the PrescQIPP landscape review

HCV ACTION CARDIFF HEPATITIS C GOOD PRACTICE ROADSHOW, 8TH DECEMBER 2017 SUMMARY REPORT

Smoking Cessation Profile: Betsi Cadwaladr University Health Board 2012/2013

THE ALL-WALES MEDICINES STRATEGY GROUP AND WELSH MEDICINES PARTNERSHIP:

Bollin, NICE Offices Manchester, Piccadilly Plaza, M1 4BT. Julian Evans (JE) Present for items 2-4. Fiona Lindop (FL) Present for items 1-6

Community pharmacy diabetes risk health promotion campaign

CARDIFF AND THE VALE OF GLAMORGAN REGIONAL PARTNERSHIP BOARD

Haematology Regional Group Meeting Monday 18 th October 2010, Antrim Hospital

Tuberculosis in Wales Annual Report 2014

The National Assembly for Wales Health and Social Care Committee is undertaking an inquiry into access to medical technologies in Wales.

Quality Standards Acute Upper Gastrointestinal Bleeding (AUGIB) Topic Expert Group

LANARKSHIRE AREA DRUG & THERAPEUTICS COMMITTEE. 2014/116 Apologies Mr John Milne, Mrs Victoria Mackinnon, Mr Smith Mr George Lindsay

SCAN Haematology Group Wednesday 23 rd May 2012 Telepresence Room, Western General Hospital, Edinburgh with videolinks to Borders, VHK and St John s

Quality Standards Epilepsy in Adults and Epilepsy in Children and Young People Topic Expert Group

Improving quality of care for epilepsy patients using a pharmacist review service

National Group for Volunteering in NHS Scotland

SOMERSET PRESCRIBING FORUM

Welsh Cardiovascular Society. Spring 2018

MINUTES OF THE CWM TAF STAKEHOLDER REFERENCE GROUP HELD ON TUESDAY 17 JULY 2012 AT THE HEALTH BOARD HEADQUARTERS, ABERCYNON

Tuberculosis in Wales Annual Report 2015

Core Standard 24. Cass Sandmann Emergency Planning Officer. Pat Fields Executive Director for Pandemic Flu Planning

Evaluation of the Cwm Taf Social Prescribing Initiative. 4 September Pharmaceutical Public Health, Public Health

CEPP National Audit Antipsychotics in Dementia

NSAIDs Change Package 2017/2018

ALL WALES MEDICINES STRATEGY GROUP (AWMSG)

Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015

Don t let falls get you down

Seasonal influenza in Wales /15

Service Specification & Contract Intermediate Stop Smoking Service & Voucher fulfilment - Pharmacy Newcastle

GWENT FORMULARY DECISIONS

GP Cluster Network Action Plan Upper Valleys Cluster

All LHBs in Wales now have some pharmacies attached to the platform and able to offer the Common Ailments Service.

Yorkshire and the Humber Strategic Clinical Networks

Prescribing Dilemmas. Sue Mulvenna Head of Pharmacy and CD Accountable Officer South Region SW 19 th May

National Therapeutic Indicators and Additional Prescribing Measures 2017/18 - Early Release Document

Developed By Name Signature Date

A Suite of Enhanced Services for. Prudent Structured Care for Adults with Type 2 Diabetes

Wales Abdominal Aortic Aneurysm Screening Programme Proposal Paper: The Implementation and Development of Elective Vascular Networks

Implementing Vitamin D Guidance. Final Minutes

Severe mental illness and substance misuse (dual diagnosis) community health and social care services Cmte minutes 1/2/16

How effective are national strategies for getting evidence into practice?

1. Introduction. 2. Role of PSI as Pharmacy Regulator

CONFIRMED INFLUENZA ISOLATES IN NORTHERN IRELAND - NICE GUIDANCE ON USE OF ANTIVIRALS NOW APPLIES

Transcription:

Enclosure No: 5/AWMSG/1114 Agenda Item No: 9 Minutes of AWPAG Meeting 24 th September 2014 Author: Chairman, AWPAG Contact: Tel: 029 20716900 E-Mail: awttc@wales.nhs.uk ALL WALES PRESCRIBING ADVISORY GROUP DRAFT Minutes of meeting held Wednesday 24 th September 2014 commencing 9.30 am At the St Michael s Centre, 10a Pen Y Pound, Abergavenny, NP7 5UD Voting members Mrs Louise Howard-Baker (Chair) Mrs Jane Barnard Mr Alan Clatworthy Mrs Sian Evans Mr Stefan Fec Miss Sophie Harding Dr Peter Horvath-Howard Mrs Sarah Isaac Dr Susanna Jacks Dr Sue Jeffs Mrs Robyn Miles Mr Jonathan Simms Mrs Fiona Walker Mrs Bev Woods In attendance (non-voting) Mr Paul Fleming Dr Rick Greville, Director Mr Paul Gimson Karen Eveleigh Miss Christine Collier Ms Kath Haines Mr Jamie Hayes Mrs Kate Jenkins Dr Tessa Lewis Pharmacist, Betsi Cadwaladr Lay member Pharmacist, Abertawe Bro Morgannwg Pharmaceutical Public Health Wales Community Pharmacist Pharmacist, Velindre GPC (Wales) Pharmacist, Hywel Dda GP, Aneurin Bevan Consultant, Aneurin Bevan ABPI Wales Industry Group Pharmacist, Aneurin Bevan Pharmacist, Cardiff and Vale Pharmacist, Cwm Taf British Generics Manufacturers ABPI Cymru Wales Public Health Wales Welsh Government Key of abbreviations ABPI Association of the British Pharmaceutical Industry AWMSG All Wales Medicines Strategy Group AWMSGSC All Wales Medicines Strategy Group Steering Committee AWPAG All Wales Prescribing Advisory Group All Wales Therapeutics and Toxicology Centre CASPA Comparative Analysis System for Prescribing Audit CEPP Clinical Effectiveness Prescribing Programme (formerly called the Prescribing Incentive Scheme) CPW Community Pharmacy Wales DHSS Department of Health and Social Services GP General Practitioner MHRA Medicines and Healthcare products Regulatory Agency NMMPB National Medicines Management Programme Board

NICE NMG NWIS PSU T&FG UHB WAPSU WeMeReC WG National Institute for Health and Care Excellence New Medicines Group NHS Wales Informatics Service Prescribing Support Unit Task and Finish Group University Health Board Welsh Analytical Prescribing Support Unit Welsh Medicines Resource Centre Welsh Government 1.0 Welcome & introduction The Chair opened the meeting and informed the group that Dr Mark Walker had been appointed to AWMSG and therefore would no longer be attending AWPAG and that Dr Sean Young had resigned from the group. The Chair extended thanks to them both for all they have done for AWPAG. The Chair also informed the group that Dr Ashok Rayani had been unwell and Dr Peter Horvath-Howard was attending as his deputy from GPC (Wales). A welcome was also extended to Karen Eveleigh from Welsh Government and to Paul Gimson, Primary Care Lead from the 1000 Lives Programme. Members introduced themselves. 2.0 Apologies Dr Mark Walker Mrs Karen Samuels Dr Hamsaraj Shetty Mr Andrew Evans Ms Marnel Owen GP, Betsi Cadwaladr Consultant, Cardiff and Vale DHSS Community Nurse, Betsi Cadwaladr 3.0 Declaration of interest. The Chair asked for any declarations of interest. Mrs Robyn Miles declared interests pertinent to the meeting. 4.0 Chair s report The Chair informed the meeting that a project proposal for a Welsh Lexicon for labelling medicines is currently being considered, and gave a brief update on the Trusted to Care report. 5.0 Minutes of previous meeting The minutes of the previous meeting were checked for accuracy. Tessa Lewis asked for it to be noted that her attendance should now be entered onto the minutes under the non-voting section as member of. It was agreed the minutes were an accurate reflection of proceedings. The Chair asked for an update of the action points: Role of Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism Tessa Lewis informed the group that this paper had now been endorsed by AWMSG. Dose Taper and Discontinuation of Biologics in Low Disease Activity Rheumatology Kath Haines informed the group that Jayne Price is still working on the points for clarification requested from the last meeting BNF Chapter Analysis: Respiratory Therapeutic Area Kath Haines informed the group that this paper is going to AWMSG on 8 October 2014 as the GP Cluster Level Comparators paper.

6.0 Feedback from AWMSG meetings held 16 July and 3 Sept 2014 Polypharmacy Guidance for Prescribing in Frail Adults The Polypharmacy Guidance for Prescribing in Frail Adults document was supported by AWMSG in July 2014. Positive feedback and requests to use the document were reported from NICE, Welsh Government and the Centre for Medicines Optimisation, Keele University. A letter had been received from the Chair of the National Specialist Advisory Group for Older People with positive comments about the guidance. The group questioned how it was to be implemented and suggested the inclusion of a summary. Sarah Isaac suggested Appendix 2 as a useful summary and agreed to share the PowerPoint presentation she has used in Hywel Dda. The recently established Prudent Prescribing Implementation Group can help with implementation of AWPAG guidance, including the polypharmacy document. JH will liaise. Action: LHB to talk to Prof John Hindle. Action: /LHB to continue working with interested parties to support the implementation of the guidance. Pharmacotherapy for Smoking Cessation Pharmacotherapy for Smoking Cessation was endorsed by AWMSG in July 2014. All Wales Advice on the Role of Oral Anticoagulants The All Wales Advice on the Role of Oral Anticoagulants document was endorsed by AWMSG in September 2014. Minor edits had been made and resources updated. It was felt that some further alteration in relation to the NICE Clinical Guidelines for AKI could not be made without consultation. NPIs 2013 2014: Analysis of Prescribing Data to March 2014 NPIs 2013 2014: Analysis of Prescribing Data to March 2014 document was supported by AWMSG in September 2014. Paul Gimson joined the group. 7.0 Presentation National prescribing Indicator (NPI) related outcome measures proposal Paul Gimson The Chair welcomed Paul Gimson, Primary Care Manager at 1000 Lives who presented the NPI related outcome measures proposal and highlighted the need for NPIs to support key principles of prudent prescribing. It was suggested that NPIs should become more outcome-focused and that 1000 Lives could support this. Difficulties with availability of outcome data were raised. Need to clarify the purpose of NPIs and who they are intended for, together with the context of their criteria for measurement. The group agreed that antidepressant and respiratory prescribing could be investigated as possible areas where NPIS could become more outcome focused. It was suggested that WAPSU pursue respiratory data and 1000 Lives look at antidepressants, with support from each other. Action: Two groups to report back to December AWPAG meeting. Action: KH and PG to co-ordinate the respiratory and antidepressant work respectively. Action: JS and BW to support respiratory work. Action: PF to provide feedback on the medicines optimisation document when it is ready to a future AWPAG meeting. Karen Eveleigh left the meeting. Jane Barnard joined the meeting. Jonathan Simms and Sarah Isaac left the meeting during the next item.

8.0 Documents for discussion 8.1 National Prescribing Indicators 2015 2016 Kate Jenkins presented the proposed NPI 2015 2016 document and referred to the notes of the AWPAG Task and Finish Sub-Group held on 21 July 2014 plus a circulated key discussion document. Discussion then followed on the document in general; order of the document, the setting of thresholds, decision support tools (e.g. ScriptSwitch) and the development of key messages. The group agreed that a summary document and PowerPoint support material would be useful and that formalised shared learning should be developed. It was requested and agreed that English averages were included within the graphs/data. Each proposed NPI was then discussed in detail, as to whether it should be included as a NPI and the appropriate measure used. Proton pump inhibitors, lipid modifying drugs, hypnotics and anxiolytics, opioid analgesics, NSAIDs and yellow card reporting were supported by the group with some minor amendments to the supporting information Inhaled corticosteroids - KJ circulated further graphs to show alternative measures to the one proposed in the document. Following lengthy discussion it was agreed to monitor all low dose inhaled corticosteroids. The All Wales Primary Care Pharmacists group will be approached to check and agree the final drug baskets for this measure. Antibiotics the proposed revised measures were agreed for the individual antibiotics/ groups of antibiotics. It was agreed that annually monitoring data to December would be appropriate to identify whether or not prescribing was reducing. Drug baskets and measures for tramadol and NSAIDs were discussed following feedback from health boards; however the group agreed with the proposals of the subgroup and the measures remained unchanged TL proposed the inclusion of an alternative, that is, non-drug measure for a NPI around patients on oral anticoagulants receiving a baseline bleeding risk assessment or a record of Time in Therapeutic Range. The group discussed the proposal and although the suggestion was supported, it was felt that it should not be included as a NPI at this point because they aren t readily available measures. Action: to explore authoring prescribing decision support message (ScriptSwitch) to support projects. Action: KJ to revise the document for consultation and present final document to December AWPAG meeting. Action: KJ to approach Primary Care Pharmacists group to check drug baskets. Action: BW to propose a project on morphine use in chronic pain, to reduce its association with palliative care only. 8.2 Advice on the Role of Oral Anticoagulants Supporting documents Tessa Lewis presented the Advice on the Role of the Oral Anticoagulants Supporting documents. The group were informed that QOF had now been updated regarding use of aspirin in AF. Discussion followed and it was agreed that in recommendation 1.1 of the Questions for Health Boards the section on flu clinics should be removed. The group also discussed the Summary for Patients and it was agreed that this needed rewording. Rick Greville, Alan Clatworthy and Jane Barnard agreed to forward rephrasing suggestions outside of the meeting. Action: to update documents, share with AWPAG (who will share more widely) then PAPIG, then present to AWMSG for information.

9.0 Verbal updates 9.1 Prescribing Dilemmas Tessa Lewis gave a verbal update on the Prescribing Dilemmas document. Dr Rob Bracchi is supporting this project and will contact contributors individually to clarify any outstanding issues. It was agreed that the section on HPV should be removed. Action: Updated document and any outstanding issues to December AWPAG meeting. 9.2 Bisphosphonates Kate Jenkins informed the group that the Bisphosphonates paper had been put out to consultation and that debate about the content had arisen. The paper will be discussed at the WOAG meeting in November, and will be amended as appropriate and then presented to AWPAG in December 2014. Action: to amend following WOAG meeting and present at December AWPAG meeting. 9.3 Medicines-related Admissions Jamie Hayes updated the group on the Medicines-related Admissions work. Currently this project is being undertaken in Wrexham and is soon to be presented to the ABPI. A WeMeReC Bulletin regarding medicines-related admissions is due to be released in October 2014. Action: JH to update members on progress at December AWPAG. 9.4 Dose Taper & Discontinuation of Biologics in Low Disease Rheumatology Work is ongoing. Action: Jayne Price to update members on progress at December AWPAG. 9.5 Antibiotic Audit Outcomes Tessa Lewis gave an update on the Antibiotic Audit Uptake. Outcomes are also being collated though fewer responses had been recieved. A suggestion was made for the audit to be given to medical students, or registrars for appraisal/revalidation support Action: Members to send any further results to. Action: to continue to collateaudit results and CEPP plans including tramadol, and present to PCDG. 10.0 Feedback from the All Wales Chief Pharmacists Committee (AWCPC) There were no items of note. 11.0 AOB There was no other business and the meeting closed. The date of next meeting Wednesday 10 th December 2014